Overview
Primary Objective:
To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis.
Secondary Objective:
To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.
Description
The study duration is one year; post treatment safety follow up visit will be conducted 4 weeks after the patient takes the last dose of teriflunomide
Eligibility
Inclusion criteria:
- Age of patients 18 years
- Patients with relapsing form of multiple sclerosis at time of screening visit.
- Signed written informed consent.
Exclusion criteria:
- Patients with hypersensitivity to teriflunomide, leflunomide, or to any excipients in the tablets.
- Liver function impairment or persisting elevations of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), greater than two times the upper limit of normal (ULN) during screening visit.
- Known history of pre-existing acute or chronic liver disease.
- Patients with significantly (as per Investigator's discretion) impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia.
- Known history of severe immunodeficiency, acute or severe active infections.
- Female patients with a positive pregnancy test at screening or women of child-bearing potential who do not agree to use effective methods of contraception throughout the course of the study.
- Male patients unwilling to use reliable contraception during the course of the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.